Evaluation of Oritavancin Combinations with Rifampin, Gentamicin, or Linezolid against Prosthetic Joint Infection-Associated Methicillin-Resistant Staphylococcus aureus Biofilms by Time-Kill Assays

Antimicrobial Agents and Chemotherapy
Qun YanRobin Patel

Abstract

The antibiofilm activity of oritavancin in combination with rifampin, gentamicin, or linezolid was evaluated against 10 prosthetic joint infection (PJI)-related methicillin-resistant Staphylococcus aureus (MRSA) isolates by time-kill assays. Oritavancin combined with rifampin demonstrated statistically significant bacterial reductions compared with those of either antimicrobial alone for all 10 isolates (P ≤ 0.001), with synergy being observed for 80% of the isolates. Oritavancin and rifampin combination therapy may be an option for treating MRSA PJI.

References

Sep 10, 2009·Antimicrobial Agents and Chemotherapy·Francis F ArhinDaniel F Sahm
Dec 17, 2010·Clinical Orthopaedics and Related Research·Fay LeungClive P Duncan
Nov 11, 2011·International Journal of Antimicrobial Agents·Francis F ArhinGregory Moeck
Mar 28, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·George G ZhanelJames A Karlowsky
Jul 17, 2012·The Journal of Antimicrobial Chemotherapy·Jorge Parra-RuizJosé Hernández-Quero
Dec 12, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Douglas R OsmonUNKNOWN Infectious Diseases Society of America
Apr 4, 2014·Clinical Microbiology Reviews·Aaron J Tande, Robin Patel
Jul 16, 2014·Antimicrobial Agents and Chemotherapy·Gengrong LinKlaudia Kosowska-Shick
Dec 22, 2016·The Journal of Antimicrobial Chemotherapy·Corinne RuppenParham Sendi
Feb 6, 2017·Diagnostic Microbiology and Infectious Disease·James A KarlowskyGeorge G Zhanel
May 30, 2017·The Open Microbiology Journal·Shriti SinghRajesh Singh

❮ Previous
Next ❯

Citations

Jun 18, 2020·Antibiotics·James B DoubPatrick R Ching

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.